FrancophonIA/ELRC3.0 huggingface dataset:
English: The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and peripheral blood mononuclear cells.
Croatian: Antivirusno djelovanje emtricitabina protiv laboratorijskih i kliničkih izolata virusa HIV-1 procijenilo se na limfoblastoidnim staničnim linijama, staničnoj liniji MAGI-CCR5 i mononuklearnim stanicama periferne krvi.
English: It is not known whether rilpivirine is excreted in human milk.
Croatian: Nije poznato izlučuje li se rilpivirin u majčino mlijeko.
English: No dose adjustment of Eviplera is suggested but caution is advised in patients with moderate hepatic impairment.
Croatian: Ne predlaže se prilagodba doze lijeka Eviplera, ali se savjetuje oprez u bolesnika s umjerenim oštećenjem jetre.
English: The degree of renal impairment was defined according to baseline CrCl (normal renal function when CrCl > 80 mL/min; mild impairment with CrCl = 50-79 mL/min; moderate impairment with CrCl = 30-49 mL/min and severe impairment with CrCl = 10-29 mL/min).
Croatian: Stupanj oštećenja bubrega definirao se prema početnom CrCl (funkcija bubrega je normalna kod CrCl > 80 ml/min; blago oštećena kod CrCl = 5079 ml/min; umjereno oštećena kod CrCl = 30 - 49 ml/min i teško oštećena kod CrCl = 1029 ml/min).
English: Switching from an efavirenz-based regimen
Croatian: Prebacivanje s režima efavirenza
English: Rilpivirine at the recommended dose of 25 mg once daily is not associated with a clinically relevant effect on QTc.
Croatian: Rilpivirin u preporučenoj dozi od 25 mg jedanput na dan nije povezan s klinički važnim učinkom na QTc.
English: If your doctor decides to stop one of the components of Eviplera or change the dose of Eviplera, you may be given emtricitabine, rilpivirine and/or tenofovir disoproxil separately or with other medicines for the treatment of HIV infection.
Croatian: Ako liječnik odluči prestati s primjenom jedne od sastavnih tvari Eviplere ili promijeniti dozu lijeka Eviplera, možda ćete dobivati emtricitabin, rilpivirin i/ili tenofovirdizoproksil odvojeno ili s drugim lijekovima za liječenje HIV-infekcije.
English: Patients with HIV-1 expressing three or more TAMs that included either the M41L or L210W RT substitution showed reduced response to tenofovir disoproxil.
Croatian: Bolesnici s virusom HIV-1 koji je izražavao tri ili više TAM-ova, među kojima i supstituciju M41L ili L210W na RT, pokazali su smanjeni odgovor na tenofovirdizoproksil.
English: These symptoms resolved after Eviplera was discontinued.
Croatian: Ti su se simptomi povukli nakon prekida terapije lijekom Eviplera.
English: When supratherapeutic doses of 75 mg once daily and 300 mg once daily of rilpivirine hydrochloride were studied in healthy adults, the maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline correction were 10.7 (15.3) and 23.3 (28.4) ms, respectively.
Croatian: Kad su se u zdravih odraslih ispitanika ispitivale doze rilpivirinklorida od 75 mg jedanput na dan odnosno 300 mg jedanput na dan koje su bile iznad terapijskih, maksimalne srednje vremenski usklađene (95% gornja granica pouzdanosti) razlike u QTcF intervalu u odnosu na placebo nakon osnovne korekcije bile su 10,7 (15,3) odnosno 23,3 (28,4) ms.
English: In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Croatian: U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja CART-a može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, koja može uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
English: For those patients failing therapy with Eviplera and who developed resistance to Eviplera cross-resistance to other approved NNRTIs (etravirine, efavirenz, nevirapine) was generally seen.
Croatian: Za one bolesnike u kojih je terapija lijekom Eviplera bila neuspješna i koji su razvili rezistenciju na lijek Eviplera u pravilu se vidjela križna rezistencija na druge odobrene nenukleozidne inhibitore reverzne transkriptaze (etravirin, efavirenz, nevirapin).
English: • rilpivirine
Croatian: • rilpivirin
English: Your doctor will discuss a different medicine if required.
Croatian: Ako to bude potrebno, liječnik će s Vama razmotriti mogućnost drugog lijeka.
English: • St. John's wort (Hypericum perforatum)
Croatian: • gospina trava (Hypericum perforatum)
English: 1 Adverse reaction identified for emtricitabine.
Croatian: 1 Nuspojava utvrđena za emtricitabin.
English: • erythromycin
Croatian: • eritromicin
English: After oral administration of the single components emtricitabine and tenofovir disoproxil, emtricitabine and tenofovir are widely distributed throughout the body.
Croatian: Nakon peroralne primjene emtricitabina i tenofovirdizoproksila kao pojedinačnih komponenti, emtricitabin i tenofovir široko se distribuiraju po cijelom tijelu.
English: • Talk to your doctor if you are over 65 years of age.
Croatian: • Ako ste stariji od 65 godina, razgovarajte sa svojim liječnikom.
English: Immune Reactivation Syndrome
Croatian: sindrom imunološke reaktivacije
English: immune reactivation syndrome
Croatian: Sindrom imunološke reaktivacije
English: Eviplera is a treatment for Human Immunodeficiency Virus (HIV) infection in adults aged
Croatian: Eviplera je namijenjena liječenju infekcije virusom humane imunodeficijencije (HIV) u odraslih u dobi od 18 ili više.
English: • Low platelet count (a type of blood cell involved in clotting blood)
Croatian: • nizak broj krvnih pločica (vrsta krvnih stanica uključena u zgrušavanje krvi)
English: The safety and efficacy of Eviplera have not been established in patients with significant underlying liver disorders.
Croatian: Nije utvrđena sigurnost i djelotvornost primjene lijeka Eviplera u bolesnika sa značajnim temeljnim poremećajima jetre.
English: The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil, including renal disorders.
Croatian: Povećano izlaganje tenofoviru može pojačati nuspojave povezane s tenofovirdizoproksilom, uključujući poremećaje bubrega.
English: The mean baseline CD4 cell count was 584 x 106 cells/L (range 42-1,484).
Croatian: Srednja vrijednost početnog broja CD4 stanica iznosila je 584 x 106 stanica/l (raspon 42 - 1484).
English: Renal function should be closely monitored (see section 4.4).
Croatian: Nužno je pomno pratiti funkciju bubrega (vidjeti dio 4.4).
English: When emtricitabine (one of the components of Eviplera) was administered to paediatric patients, the following adverse reactions were observed more frequently in addition to the adverse reactions reported in adults: anaemia was common (9.5%) and skin discolouration (increased pigmentation) was very common (31.8%) in paediatric patients (see section 4.8, Tabulated summary of adverse reactions).
Croatian: Kada je emtricitabin (jedna od djelatnih tvari lijeka Eviplera) primijenjen pedijatrijskim bolesnicima, sljedeće nuspojave su zabilježene učestalije uz nuspojave zabilježene kod odraslih osoba: anemija je bila česta (9,5%) i promjena boje kože (pojačana pigmentacija) je bila vrlo česta (31,8%) u pedijatrijskih bolesnika (vidjeti dio 4.8, Tablični sažetak nuspojava).
English: There were no new safety findings compared with the known safety profile of rilpivirine in HIV-1 infected adults (see sections 4.2, 4.4 and 5.2).
Croatian: U odraslih zaraženih virusom HIV-1 nije bilo novih sigurnosnih podataka u usporedbi s poznatim profilom sigurnosti rilpivirina (vidjeti dijelove 4.2, 4.4 i 5.2).
English: Bone abnormalities (infrequently contributing to fractures) may be associated with proximal renal tubulopathy (see section 4.8).
Croatian: Abnormalnosti kostiju (koje rijetko pridonose prijelomima) mogu biti povezane s proksimalnom bubrežnom tubulopatijom (vidjeti dio 4.8).
English: Emtricitabine and tenofovir individually and in combination have shown activity against HBV in pharmacodynamic studies (see section 5.1).
Croatian: U farmakodinamičkim ispitivanjima, emtricitabin i tenofovir pokazali su djelovanje protiv HBV-a pojedinačno i u kombinaciji (vidjeti dio 5.1).
English: Considering all of the available in vitro data and data generated in previously untreated patients, the following resistance-associated mutations in HIV-1 RT, when present at baseline, may affect the activity of Eviplera: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L and the combination of L100I and K103N.
Croatian: Uzimajući u obzir sve dostupne in vitro podatke i podatke dobivene od bolesnika koji prethodno nisu bili liječeni, na djelovanje lijeka Eviplera mogu utjecati sljedeće mutacije HIV-1 RT povezane s rezistencijom, kad su prisutne na početku: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L i kombinacija L100I i K103N.
English: Antacids (e.g. aluminium or magnesium hydroxide, calcium carbonate)
Croatian: Antacidi (npr. aluminijev ili magnezijev hidroksid, kalcijev karbonat)
English: Resistance to rilpivirine2 Cross-resistance3 to etravirine efavirenz nevirapine
Croatian: Križna rezistencija3 na etravirin efavirenz nevirapin
English: Eviplera should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or other cytidine analogues, such as lamivudine (see section 4.5).
Croatian: Eviplera se ne smije primjenjivati istovremeno s drugim lijekovima koji sadrže emtricitabin, tenofovirdizoproksil, tenofoviralafenamid ili druge analoge citidina, kao što je lamivudin (vidjeti dio 4.5).
English: Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Croatian: Bolesnici s kroničnim hepatitisom B ili C liječeni antiretrovirusnom terapijom, izloženi su povećanom riziku od teških i potencijalno smrtonosnih jetrenih nuspojava.
English: Discontinued study drug due to AE or deathd
Croatian: Prekid primjene ispitivanog lijeka zbog nuspojave ili smrtid
English: HIV patients with liver disease (including chronic hepatitis B or C), who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications.
Croatian: Bolesnici s HIV-om s bolešću jetre (uključujući kronični hepatitis B ili C), koji se liječe antiretrovirusnim lijekovima, izloženi su većem riziku od pojave teških i potencijalno životno opasnih komplikacija s jetrom.
English: Lower exposures of rilpivirine (one of the components of Eviplera) were observed during pregnancy; therefore viral load should be monitored closely.
Croatian: Tijekom trudnoće opažene su manje izloženosti rilpivirinu (jedna od komponenti lijeka Eviplera); stoga je potrebno pažljivo pratiti virusno opterećenje.
English: Virologic response to tenofovir disoproxil was not reduced in patients with HIV-1 that expressed the abacavir/emtricitabine/lamivudine resistance-associated M184V substitution.
Croatian: Virološki odgovor na tenofovirdizoproksil nije bio smanjen u bolesnika s HIV-1 koji je izražavao supstituciju M184V povezanu s rezistencijom na abakavir/emtricitabin/lamivudin.
English: Sofosbuvir/Emtricitabine
Croatian: Sofosbuvir/emtricitabin
English: Eviplera contains lactose and sunset yellow aluminium lake (E110)
Croatian: Eviplera sadrži laktozu i boju sunset yellow aluminium lake (E110)
English: • If you notice within 12 hours of the time you usually take Eviplera, you must take the tablet as soon as possible.
Croatian: • Ako to primijetite a prošlo je manje od 12 sati od vremena kad obično uzimate Evipleru, tabletu morate uzeti što prije.
English: In treatment-naïve patients, the most frequently reported adverse reactions considered possibly or probably related to rilpivirine hydrochloride and emtricitabine/tenofovir disoproxil were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%) (pooled data from the Phase III clinical studies C209 and C215, see section 5.1).
Croatian: U bolesnika koji prethodno nisu bili liječeni, najčešće zabilježene nuspojave za koje se smatra da su moguće ili vjerojatno povezane s rilpivirinkloridom i emtricitabinom/tenofovirdizoproksilom bile su mučnina (9%), omaglica (8%), abnormalni snovi (8%), glavobolja (6%), proljev (5%) i nesanica (5%) (objedinjeni podaci iz kliničkih ispitivanja III. faze C209 i C215, vidjeti dio 5.1).
English: There is limited information regarding the use of Eviplera in patients with mild or moderate hepatic impairment (Child-Pugh-Turcotte (CPT) Score A or B).
Croatian: Postoje ograničene informacije o primjeni lijeka Eviplera u bolesnika s blagim ili umjerenim oštećenjem jetre (Child-Pugh-Turcotte (CPT) stadij A ili B).
English: Of the 469 Eviplera-treated patients [317 patients who switched to Eviplera at baseline (Eviplera arm) and 152 patients who switched at week 24 (Delayed Switch arm)], a total of 7 patients were analysed for resistance development and all had genotypic and phenotypic data available.
Croatian: Od 469 bolesnika liječenih lijekom Eviplera [317 bolesnika prebačenih na lijek Eviplera na početku (skupina na lijeku Eviplera) i 152 bolesnika koji su se prebacili u 24. tjednu (skupina s kasnim prebacivanjem)], analiza na razvoj rezistencije provedena je u ukupno 7 bolesnika i svi su imali dostupne genotipske i fenotipske podatke.
English: Emtricitabine exposures were not affected by food.
Croatian: Hrana nije utjecala na izloženost emtricitabinu.
English: In virologically suppressed HIV-1 infected patients In study GS-US-264-0106, 4 of the 469 patients who switched from a ritonavir-PI-based regimen to Eviplera had HIV-1 with reduced susceptibility to at least one component of Eviplera through week 48.
Croatian: U ispitivanju GS-US-264-0106, 4 od 469 bolesnika prebačenih s režima ritonavirom pojačanim IP na lijek Eviplera imalo je HIV-1 sa smanjenom osjetljivošću na barem jednu komponentu lijeka Eviplera do 48. tjedna.
English: H2-RECEPTOR ANTAGONISTS Famotidine/Emtricitabine
Croatian: ANTAGONISTI H2-RECEPTORA
English: The antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood lymphocytes.
Croatian: Antivirusno djelovanje tenofovira protiv laboratorijskih i kliničkih izolata HIV-1 procijenilo se na limfoblastoidnim staničnim linijama, primarnim monocitnim/makrofagnim stanicama i limfocitima periferne krvi.
English: Pharmacokinetic parameters were mainly determined following administration of single doses of emtricitabine 200 mg or tenofovir disoproxil 245 mg to non-HIV infected patients with varying degrees of renal impairment.
Croatian: Farmakokinetički parametri određeni su uglavnom nakon primjene jednokratnih doza od 200 mg emtricitabina ili 245 mg tenofovirdizoproksila kod bolesnika koji nisu bili inficirani virusom HIV-a, a imali su različiti stupanj oštećenja bubrega.
English: Hypromellose, indigo carmine aluminium lake, lactose monohydrate, polyethylene glycol, red iron oxide, sunset yellow aluminium lake (E110), titanium dioxide, and triacetin.
Croatian: Film-ovojnica: hipromeloza, boja indigo carmine aluminium lake, laktoza hidrat, polietilenglikol, crveni željezov oksid, boja sunset yellow aluminium lake (E110), titanijev dioksid i triacetin.
English: 7 This adverse reaction was identified through post-marketing surveillance for Eviplera (fixed-dose combination) but not observed in randomised controlled clinical studies for Eviplera.
Croatian: 7 Ova nuspojava bila je identificirana tijekom praćenja lijeka Eviplera nakon stavljanja lijeka u promet (kombinacija s fiksnom dozom) no nije zabilježena u randomiziranim kontroliranim kliničkim ispitivanjima za lijek Eviplera.
English: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Croatian: U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja liječenja CARTom mogu nastati upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
English: The combination of emtricitabine, rilpivirine and tenofovir disoproxil has been studied as the component products in treatment-naïve patients (Phase III studies C209 and C215).
Croatian: Kombinacija emtricitabina, rilpivirina i tenofovirdizoproksila ispitana je njihovom primjenom kao zasebnih lijekova u bolesnika koji prethodno nisu bili liječeni (ispitivanja III. faze C209 i C215).
English: Animal studies do not indicate harmful effects of emtricitabine, rilpivirine hydrochloride or tenofovir disoproxil on fertility.
Croatian: Ispitivanja na životinjama ne ukazuju da emtricitabin, rilpivirinklorid ili tenofovirdizoproksil imaju štetan učinak na plodnost.
English: Eviplera should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil or tenofovir alafenamide.
Croatian: Eviplera se ne smije primjenjivati istovremeno s drugim lijekovima koji sadrže emtricitabin, tenofovirdizoproksil ili tenofoviralafenamid.
English: Interaction not studied with any components of Eviplera.
Croatian: Interakcija nije ispitana ni s jednom komponentom lijeka Eviplera.
English: Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosinerelated adverse reactions.
Croatian: Istovremena primjena tenofovirdizoproksila i didanozina rezultira 40 - 60% -tnim povećanjem sistemske izloženosti didanozinu, što može povećati rizik od nuspojava povezanih s didanozinom.
English: Table 2: Tabulated summary of adverse reactions to Eviplera based on clinical study and post-marketing experience with Eviplera and its individual components
Croatian: Tablica 2: Tablični sažetak nuspojava na lijek Eviplera na temelju kliničkog ispitivanja i iskustva nakon stavljanja lijeka u promet lijeka Eviplera i njegovih pojedinačnih djelatnih tvari
English: • Other medicines used for HIV infection: Non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Croatian: • Drugi lijekovi za liječenje HIV-infekcije: Nenukleozidni inhibitori reverzne transkriptaze (NNRTI).
English: • omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole (proton pump inhibitors that are medicines used to prevent and treat stomach ulcers, heartburn, acid reflux disease)
Croatian: • omeprazol, lanzoprazol, rabeprazol, pantoprazol i ezomeprazol (inhibitori protonske pumpe, a to su lijekovi koji se primjenjuju za sprječavanje i liječenje čireva želuca, žgaravice i bolesti vraćanja želučane kiseline)
English: Use of Eviplera should be avoided with concurrent or recent use of a nephrotoxic medicinal product (see section 4.5).
Croatian: Primjenu lijeka Eviplera treba izbjegavati kod istovremene ili nedavne primjene nefrotoksičnih lijekova (vidjeti dio 4.5).
English: Patients were randomised in a 1:1 ratio to receive either rilpivirine hydrochloride 25 mg (n = 686) once daily or efavirenz 600 mg (n = 682) once daily in addition to a BR.
Croatian: Bolesnici su bili randomizirani u omjeru 1:1 u skupinu koja je primala rilpivirinklorid 25 mg (n = 686) jedanput na dan i skupinu koja je primala efavirenz 600 mg (n = 682) jedanput na dan uz osnovni terapijski režim.
English: • Yellow skin or eyes, itching or pain in the abdomen (tummy) caused by inflammation of the liver
Croatian: • žuta boja kože ili očiju, svrbež ili bol u trbuhu prouzročen upalom jetre
English: In addition, a K70E substitution in HIV-1 RT has been selected by tenofovir and results in low-level reduced susceptibility to abacavir, emtricitabine, tenofovir and lamivudine.
Croatian: Osim toga, supstitucija K70E u HIV-1 RT selektivno je izdvojena tenofovirom i dovela je do niske razine smanjene osjetljivosti na abakavir, emtricitabin, tenofovir i lamivudin.
English: • the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
Croatian: • antikonvulzivi karbamazepin, okskarbazepin, fenobarbital, fenitoin
English: • Decreases in phosphate levels in the blood
Croatian: • snižene razine fosfata u krvi
English: Patients were switched from efavirenz/emtricitabine/tenofovir disoproxil to Eviplera without a washout period.
Croatian: Bolesnici su bili prebačeni s efavirenza/emtricitabina/tenofovirdizoproksila na Evipleru bez razdoblja ispiranja prethodno uzimanih lijekova.
English: The pharmacokinetics of emtricitabine has not been studied in patients with varying degrees of hepatic insufficiency.
Croatian: Farmakokinetika emtricitabina nije ispitana u bolesnika s različitim stupnjevima jetrene insuficijencije.
English: Eviplera should not be co-administered with the following medicinal products as significant decreases in rilpivirine plasma concentrations may occur (due to cytochrome P450 [CYP]3A enzyme induction or gastric pH increase), which may result in loss of therapeutic effect of Eviplera:
Croatian: Eviplera se ne smije istovremeno primjenjivati sa sljedećim lijekovima, jer mogu nastati značajna smanjenja koncentracije rilpivirina u plazmi (zbog indukcije enzima citokroma P450 [CYP]3A ili povišenja želučanog pH), što može rezultirati gubitkom terapijskog učinka lijeka Eviplera:
English: There were 7/317 patients (2%) in the Eviplera arm and 6/152 patients (4%) in the Delayed Switch arm who permanently discontinued study drug due to a treatment-emergent adverse event (TEAE).
Croatian: U skupini na lijeku Eviplera bilo je 7/317 bolesnika (2%), a u skupini s odgođenim prebacivanjem 6/152 (4%) bolesnika koji su trajno prekinuli uzimanje ispitivanog lijeka zbog štetnog događaja koji se pojavio uz liječenje.
English: The breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells.
Croatian: Uslijed oštećenja stanica bubrežnih kanalića može doći do razlaganja mišića, omekšavanja kostiju (uz bolove u kostima i katkad lomove), bolova u mišićima, slabosti mišića i smanjenja koncentracije kalija ili fosfata u krvi.
English: In the week 96 pooled resistance analysis for patients receiving emtricitabine/tenofovir disoproxil + rilpivirine hydrochloride in the Phase III clinical studies C209 and C215, there were 78 virologic failure patients with genotypic resistance information available for 71 of those patients.
Croatian: U analizi objedinjenih podataka o rezistenciji iz 96. tjedna za bolesnike koji su primali emtricitabin/tenofovirdizoproksil + rilpivirinklorid u kliničkim ispitivanjima III. faze C209 i C215, u 78 bolesnika postojao je virološki neuspjeh, a genotipski podaci o rezistenciji bili su dostupni za 71 od tih bolesnika.
English: 6 Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.
Croatian: 6 Ispitivanje provedeno emtricitabinom/rilpivirinom/tenofoviralafenamidom u kombiniranoj tableti s fiksnom dozom.
English: Patients were randomised in a 2:1 ratio to either switch to Eviplera at baseline (Eviplera arm, n = 317), or stay on their baseline antiretroviral regimen for 24 weeks (SBR arm, n = 159) before switching to Eviplera for an additional 24 weeks (Delayed Switch arm, n = 152).
Croatian: Bolesnici su bili randomizirani u omjeru 2:1 za prebacivanje ili na lijek Eviplera na početku (skupina na lijeku Eviplera, n=317) ili ostanak na svom početnom antiretrovirusnom režimu tijekom 24 tjedna (skupina ostala na početnom režimu liječenja, n=159) prije prebacivanja na lijek Eviplera tijekom dodatna 24 tjedna (skupina s kasnim prebacivanjem, n=152).
English: The pharmacokinetics of tenofovir has been studied in patients with hepatic impairment and no dose adjustment is required in these patients.
Croatian: Farmakokinetika tenofovira ispitana je u bolesnika s oštećenjem jetre i u tih bolesnika nije potrebna prilagodba doze.